Zhuzhou pharm company signs huge licensing deal
Biopharmaceutical company Zonsen PepLib Biotech said in a company statement on Monday that it has struck a global licensing deal with Swiss multinational pharmaceutical company Novartis to develop a new peptide-based treatment, netting an upfront payment of $50 million. The agreement focuses on an undisclosed asset used in radioligand therapy, a precision cancer treatment that delivers…









